Mydecine Innovations Group Inc (OTC:MYCOF, NEO:MYCO) has announced the appointment of Dr Victoria Hale to the company’s board of directors.
The company noted that Dr Hale is a pharmaceutical scientist and executive, as well as a global health social entrepreneur. She currently serves as chair of the board of the Multidisciplinary Association for Psychedelic Studies (MAPS), a non-profit research and educational organization leading the psychedelics sector in new medicine development.
MAPS works to raise awareness of psychedelics and help scientists design, fund and obtain regulatory approval of studies measuring the safety and effectiveness of psychedelics for therapeutic use.
“We are thrilled to welcome Dr Hale to Mydecine's board of directors. Her unique experience in drug development and psychedelic medicine will be a valued addition to the company's expertise,” said Mydecine chief science officer Rob Roscow in a statement. “Strengthening our board with industry leaders like Victoria is one of the ways Mydecine is preparing for future growth.”
READ: Mydecine submits pre-IND briefing package to FDA for MYCO-001 smoking cessation clinical trial
“With Victoria’s extensive experience and her commitment to bringing life-changing treatments to those who need them, our board members unanimously agreed that she will be an added asset to the company. Like the team at Mydecine, Victoria has a strong passion for working to improve public health outcomes,” added Mydecine CEO Josh Bartch.
As a global health entrepreneur committed to reducing health inequities, the company noted that Dr Hale has raised $230 million in philanthropy for drug development and has successfully guided several new medicines through the requirements of the US Food and Drug Administration (FDA) and other regulatory agencies.
With previous drug development experience at the FDA and Genentech Inc., Dr Hale earned her Ph.D. in Pharmaceutical Chemistry from University of California San Francisco, where she is Adjunct Professor of Bioengineering and Experimental Sciences.
She founded the first US non-profit pharmaceutical company in 2001, OneWorld Health, and served as chairman and CEO until 2008, and Chair Emeritus until 2011. She then founded Medicines360, a non-profit pharmaceutical company dedicated to developing medicines for women and children, including pregnant women.
Dr Hale is a MacArthur Fellow, a member of the US National Academy of Medicine, and serves on several other boards. She has been recognized as an outstanding global social entrepreneur by the Schwab Foundation, the Skoll Foundation and Ashoka.
“There is a tremendous unmet need for effective treatments for mental health disorders,” said Dr. Hale. “I’m excited to work with Mydecine as their team explores new therapies to help address the global mental health crisis.”
Mydecine Innovations is a biotechnology and digital technology company developing innovative first and second-generation novel therapeutics for the treatment of mental health and addiction using world-class technology and drug development infrastructure.
The company was founded in 2020 to address a significant unmet need and lack of innovation in mental health and therapeutic treatment environments. Its global team is dedicated to efficiently developing new therapeutics to treat PTSD, depression, anxiety, addiction and other mental health disorders.
Mydecine is headquartered in Denver, Colorado, USA, with international offices in Leiden, Netherlands.
Contact the author at jon.hopkins@proactiveinvestors.com